Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab

Ítems similars

• T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
  per: Anna Sureda-Balari, et al.
  Publicat: (2022-10-01)
• Severe hypomagnesaemia with tetany following ESHAP protocol
  per: Majumdar, Gautam
  Publicat: (2002)
• Efficacy of ESHAP versus ICE plus dexamethasone (DICE) as salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
  per: Pattamaporn Boonlerd, et al.
  Publicat: (2023-12-01)
• R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome
  per: Alejandro Martín, et al.
  Publicat: (2009-05-01)
• The word that did (not) escape: Ovde [here] and tamo [there]
  per: Miloradović Sofija R.
  Publicat: (2016-01-01)